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Survival and Long-Term Biochemical Cure in Medullary
Thyroid Carcinoma in Denmark 1997–2014:
A Nationwide Study
Jes Sloth Mathiesen,1,2 Jens Peter Kroustrup,3 Peter Vestergaard,3,4 Kirstine Stochholm,5,6
Per Løgstrup Poulsen,5 Åse Krogh Rasmussen,7 Ulla Feldt-Rasmussen,7 Sten Schytte,8
Stefano Christian Londero,8 Henrik Baymler Pedersen,9 Christoffer Holst Hahn,10 Jens Bentzen,11
Sören Möller,2,12 Mette Gaustadnes,13 Maria Rossing,14 Finn Cilius Nielsen,14 Kim Brixen,2
Anja Lisbeth Frederiksen,2,15 Christian Godballe,1 and the Danish Thyroid Cancer Group (DATHYRCA)
Background: Survival of medullary thyroid carcinoma (MTC) subgroups in relation to the general population is
poorly described. Data on the factors predicting long-term biochemical cure in MTC patients are nonexistent at a
population level. A nationwide retrospective cohort study of MTC in Denmark from 1997 to 2014 was conducted,
aiming to detect subgroups with survival similar to that of the general population and to identify prognostic factors
for disease-specific survival and long-term biochemical cure.
Methods: The study included 220 patients identified from the nationwide Danish MTC cohort between 1997 and 2014.
As a representative sample of the general population, a reference population matched 50:1 to the MTC cohort was used.
Results: Patients diagnosed with hereditary MTC by screening (hazard ratio [HR] = 1.5 [confidence interval (CI) 0.5–
4.3]), patients without regional metastases (HR = 1.4 [CI 0.9–2.3]), and patients with stage I (HR = 1.3 [CI 0.6–3.1]),
stage II (HR = 1.1 [CI 0.6–2.3]), and III (HR = 1.3 [CI 0.4–4.2]) disease had an overall survival similar to the reference
population. On multivariate analysis, the presence of distant metastases (HR = 12.3 [CI 6.0–25.0]) predicted worse
disease-specific survival, while the absence of regional lymph node metastases (odds ratio = 40.1 [CI 12.0–133.7]) was
the only independent prognostic factor for long-term biochemical cure.
Conclusions: Patients with hereditary MTC diagnosed by screening, patients without regional metastases, and patients
with stages I, II, and III disease may have similar survival as the general population. The presence of distant metastases
predicted worse disease-specific survival, while the absence of regional metastases predicted long-term biochemical cure.
Keywords: medullary thyroid carcinoma, survival, biochemical cure, nationwide, population-based, Denmark
Introduction
Medullary thyroid carcinoma (MTC) is a rareneuroendocrine tumor with an incidence of 0.19/
100,000 per year and a prevalence of 3.8/100,000 inhabitants.
It is divided into sporadic MTC (SMTC) and hereditary MTC
(HMTC), accounting for approximately 75% and 25% of
cases, respectively (1).
The survival of MTC patients is in general inferior to that
of the general population. This has been demonstrated in
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several population-based studies (2–6). At the subgroup le-
vel, however, survival with regards to the general population
is poorly described. Thus, only one study has investigated this
particular aspect (6). That study concluded that survival did
not differ from that of the general population in the following
groups: patients with a family history of MTC detected by
screening, those with a tumor size <1 cm, and those with
early-stage disease at diagnosis. However, as only 60% (148/
247) of the study cohort received the currently recommended
thyroid surgery (total thyroidectomy) (7), it is questionable if
results are applicable to contemporary MTC series.
Disease-specific survival of MTC patients is strongly de-
pendent on the age and stage at diagnosis. This has been well
recognized for decades (8–13). The significance of sex as a
prognostic factor, however, remains controversial (8,10–13).
The best possible outcome for MTC patients following
treatment is biochemical cure. Although being an extremely
pertinent outcome, there is a paucity of data from population-
based studies. In fact, only one study has investigated bio-
chemical cure and associated predictors at a population level
(12). The study, however, defined biochemical cure as nor-
mal calcitonin levels within the first six months following
surgery, and therefore did not take into account the 5–21% of
MTC patients who postoperatively achieve initial biochem-
ical cure but later develop biochemical recurrence (12,14–
22). Also, the study included only 36% (899/2490) of the
entire MTC cohort, causing external validity issues.
Consequently, the first population-based study of an un-
selected nationwide MTC cohort was conducted, aiming to
identify prognostic factors for long-term biochemical cure
and to detect prognostic factors for disease-specific survival
and MTC subgroups with survival inferior or similar to that
of the general population.
Methods
Patients
This retrospective cohort study included 220 unique pa-
tients diagnosed with MTC in Denmark between January 1,
1997, and December 31, 2014.
An MTC cohort, initially comprising 476 patients diagnosed
with MTC in Denmark between January 1960 and December
2014, was constructed through three nationwide registries: the
Danish Thyroid Cancer Database, the Danish Cancer Registry,
and the Danish Pathology Register (23–25). This has been
described in detail previously (1,26). From this cohort, the 224
patients diagnosed nationwide in the period 1997–2014, where
coverage of the entire country was considered complete, were
extracted. After exclusion of four patients diagnosed at autopsy,
220 patients were included. Of these, 219 had histologically
diagnosed MTC, while one had cytologically and biochemi-
cally diagnosed MTC verified by positive calcitonin staining
and basal serum calcitonin >2000 pg/mL.
The investigation was approved by the Danish Health
Authority (3-3013-395/3) and the Danish Data Protection
Agency (18/17801).
Methods
Data were provided by the Danish Thyroid Cancer Data-
base. Where this was insufficient, data were drawn from the
Danish Cancer Registry, the Danish Pathology Register, or
medical records.
Predictor variables were sex, age, MTC type (SMTC or
HMTC by screening or symptoms), tumor-node-metastasis
(TNM) status, multifocality, and bilaterality. Classification of
MTC type was primarily based on the absence or presence of
REarranged during Transfection (RET) germline mutations. RET
testing and classification of MTC type have been described
elsewhere (1,27,28). TNM staging was performed according to
the seventh and eighth editions of the American Joint Committee
on Cancer Staging Manual and was based on clinical and
pathological assessment (29,30). In case of discrepancy, patho-
logical overruled clinical staging. Multifocality was defined as
more than one MTC focus, while bilaterality was defined as the
presence of at least one MTC focus in both lobes.
Outcome variables were overall survival, disease-specific
survival, and long-term biochemical cure.
Survival
Survival time was calculated as the time from MTC di-
agnosis until death, emigration, or last follow-up ( January 1,
2018), whichever came first. For calculation of overall sur-
vival and disease-specific survival, all deaths and deaths due
to MTC were considered as an event, respectively.
To compare overall survival between MTC patients and
the general population, a reference population was created.
Fifty people per each MTC patient were randomly selected
from the Civil Registration System (www.cpr.dk) as controls.
These were matched to the MTC case by sex, birth year, and
birth month. All controls had to be alive at the date of MTC
diagnosis for their respective cases. Additionally, the refer-
ence population could not include patients from the Danish
MTC cohort from 1960 to 2014 (1), nor could it include first-
or second-degree relatives to this cohort.
Biochemical cure
Long-term biochemical cure was defined as undetectable
basal serum calcitonin at last biochemical follow-up in pa-
tients who had received no other treatment beyond initial
surgery.
Statistical analysis
Continuous variables were reported as the median and
interquartile range (IQR). Survival data were analyzed by the
Kaplan–Meier method. Cox’s proportional hazards regres-
sion model was employed in univariate and multivariate
analyses of survival. Cox’s proportional hazards models were
tested for satisfying the proportional hazards assumption. If
deviations from the assumption were detected, robust stan-
dard errors in the Cox model were estimated to take into
account the added uncertainty. Logistic regression was used
in univariate and multivariate analyses for long-term bio-
chemical cure. p-Values <0.05 were considered significant.
Multiple testing was adjusted by the Bonferroni method (31).
All analyses were done using Stata v15.1 (StataCorp).
Results
A total of 220 patients were included in the study. Patient
characteristics are shown in Table 1. The overall female-to-
male ratio was 1.47 [confidence interval (CI) 1.08–1.87].
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In the 53 HMTC patients, the following RET mutations
were detected: C611W (n = 3), C611Y (n = 31), C618F (n = 1),
C618Y (n = 3), C620R (n = 4), C634R (n = 1), C634Y + Y791F
(n = 1), L790F (n = 1), V804M (n = 1), A883F (n = 1), and
M918T (n = 6). Several of these have been reported previ-
ously (32–39).
Survival
The median follow-up time was 6.8 years (IQR 3.4–12.7).
At last follow-up, 76 patients had died. Of these, 51 had died
from MTC, while 25 had died from other causes. This yielded
5-, 10-, 15-, and 20-year overall survival rates of 75% [CI 69–
80], 64% [CI 56–70], 58% [CI 49–65], and 56% [CI 47–64],
respectively. Corresponding numbers for disease-specific
survival were 82% [CI 76–86], 75% [CI 67–80], 71% [CI 63–
78], and 69% [CI 59–77], respectively.
The reference population comprised 11,000 controls (6550
females). Table 2 shows the overall survival in MTC subgroups
in relation to their corresponding reference population.
Analyses of prognostic factors for disease-specific survival
in univariate and multivariate analyses are shown in Table 3.
Several factors were significant on multivariate analysis
(sex, and T4, N, and M category). However, when modified by
Bonferroni correction, only the M category remained signif-
icant ( p < 0.001). Conducting a similar multivariate analysis,
where age at diagnosis was treated as a continuous variable,
younger age significantly predicted better disease-specific
survival, even after Bonferroni testing ( p < 0.001).
Biochemical cure
For assessment of long-term biochemical cure, only the
200 patients treated with at least total thyroidectomy were
Table 1. Characteristics of 220 Patients with Medullary Thyroid Carcinoma in Denmark, 1997–2014
Hereditary
All Sporadic By symptoms By screening
Characteristics (n = 220) (n = 167) (n = 10) (n = 43)
At diagnosis
Sex, n (%)
Female 131 (60) 105 (63) 7 (70) 19 (44)
Male 89 (40) 62 (37) 3 (30) 24 (56)
Age (years), median (IQR) 53 (39–66) 57 (45–69) 36 (18–59) 37 (22–48)
MEN2 syndrome, n (%)
MEN2A 46 (87) 7 (70) 39 (91)
MEN2B 7 (13) 3 (30) 4(9)
Thyroid surgery, n (%)
No thyroid surgery 12 (5) 11 (7) 0 1 (2)
Diagnostic open biopsy 5 (2) 5 (3) 0 0
Hemithyroidectomy 3 (1) 3 (2) 0 0
Total thyroidectomy 200 (91) 148 (89) 10 (100) 42 (98)
Lymph node surgery, n (%)
No lymph node surgery 39 (18) 28 (17) 2 (20) 9 (21)
Lymph node extirpation 39 (18) 31 (19) 0 8 (19)
Modified neck dissection 125 (57) 93 (56) 6 (60) 26 (60)
Classic neck dissection 17 (8) 15 (9) 2 (20) 0
T category, n (%)
T0 1 (0) 1 (1) 0 0
T1 91 (41) 49 (29) 5 (50) 37 (86)
T2 57 (26) 53 (32) 1 (10) 3 (7)
T3 27 (12) 23 (14) 2 (20) 2 (5)
T4 42 (19) 39 (23) 2 (20) 1 (2)
Tx 2 (1) 2 (1) 0 0
N category, n (%)
N0 103 (47) 75 (45) 2 (20) 26 (60)
N1 117 (53) 92 (55) 8 (80) 17 (40)
M category, n (%)
M0 199 (90) 146 (87) 10 (100) 43 (100)
M1 21 (10) 21 (13) 0 0
TNM stage,a n (%)
I 56 (25) 31 (19) 1 (10) 24 (56)
II 40 (18) 37 (22) 1 (10) 2 (5)
III 17 (8) 10 (6) 1 (10) 6 (14)
IV 106 (48) 88 (53) 7 (70) 11 (26)
Unknown 1 (0) 1 (1) 0 0
Due to rounding up, not all sums of percentages fit.
aStaging was based on the American Joint Committee on Cancer seventh and eighth editions (29,30).
IQR, interquartile range; MEN2, multiple endocrine neoplasia 2; T, tumor; N, node; M, metastasis.
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considered. Of these, data were available for 194 patients.
Seventy (36%) and 124 (64%) patients were classified with or
without long-term biochemical cure, respectively. In the latter
group, five patients had undetectable calcitonin at last bio-
chemical follow-up, but as they had received additional treat-
ment (reoperation or external beam radiotherapy) between
initial surgery and last biochemical follow up, they were re-
garded as not cured. Median time to last biochemical follow-up
in all 194 patients was 5.5 years (IQR 3.1–9.8 years), and in the
70 patients achieving long-term cure, it was 5.6 years (IQR 3.3–
10.7 years). Among the long-term cured patients, all but one
(who died of other causes seven months after initial surgery)
had more than two years of biochemical follow-up.
Characteristics of the patients who were long-term
cured and those who were not are depicted in Table 4. Five
percent (5/100) of the node-positive patients achieved
long-term biochemical cure. Of these, four had only one
lymph node metastasis, while one had three. Meanwhile,
69% (65/94) of the node-negative patients were cured.
Analyses of prognostic factors for long-term biochemical
cure in univariate and multivariate analyses are shown in
Table 5.
For the 124 patients who did not achieve long-term cure,
the 5-, 10-, 15-, and 20-year disease-specific survival rates
were 84% [CI 76–89], 72% [CI 61–80], 67% [CI 54–76], and
63% [CI 49–74], respectively.
Table 2. Overall Survival in Subgroups of Patients with Medullary Thyroid Carcinoma in Denmark
1997–2014 in Relation to their Age- and Sex-Matched Reference Population
MTC population Reference population Univariate analysis
MTC subgroup Total, n Deaths, n (%) Total, n Deaths, n (%) HR [CI] p-Value
All 220 76 (35) 11,000 1815 (17) 2.6 [2.0–3.4] <0.001d
Age at diagnosis (years)
<21 14 1 (7) 700 3 (0.4) 17.2 [1.8–165.7] 0.014
21–40 48 7 (15) 2400 46 (2) 8.4 [3.6–19.4] <0.001d
41–60 81 22 (27) 4050 384 (9) 3.7 [2.3–5.9] <0.001d
>61 77 46 (60) 3850 1382 (36) 2.7 [1.9–3.9] <0.001d
Sex
Female 131 39 (30) 6550 1054 (16) 2.2 [1.6–3.1] <0.001d
Male 89 37 (42) 4450 761 (17) 3.3 [2.2–4.8] <0.001d
MTC type
HMTC, by screening 43 4 (9) 2150 135 (6) 1.5 [0.5–4.3] 0.402
HMTC, by symptoms 10 3 (30) 500 57 (11) 3.4 [1.0–10.7] 0.041
SMTC 167 69 (41) 8350 1623 (19) 2.9 [2.2–3.7] <0.001d
T categorya
T1 91 16 (18) 4550 468 (10) 1.9 [1.1–3.3] 0.017d
T2 57 20 (35) 2850 435 (15) 2.7 [1.7–4.2] <0.001
T3 27 12 (44) 1350 327 (24) 2.5 [1.2–4.9] 0.009d
T4 42 27 (64) 2100 557 (27) 4.6 [3.1–6.8] <0.001
N category
N0 103 19 (18) 5150 717 (14) 1.4 [0.9–2.3] 0.160d
N1 117 57 (49) 5850 1098 (19) 3.9 [2.9–5.3] <0.001d
M category
M0 199 56 (28) 9950 1549 (16) 2.1 [1.6–2.8] <0.001d
M1 21 20 (95) 1050 266 (25) 31.5 [19.3–51.4] <0.001
TNM stageb
I 56 6 (11) 2800 232 (8) 1.3 [0.6–3.1] 0.525d
II 40 8 (20) 2000 369 (18) 1.1 [0.6–2.3] 0.696
III 17 3 (18) 850 114 (13) 1.3 [0.4–4.2] 0.617
IV 106 59 (56) 5300 1098 (21) 4.4 [3.3–6.1] <0.001d
Multifocalityc
Yes 68 17 (25) 3400 339 (10) 2.9 [1.7–4.9] <0.001d
No 132 39 (30) 6600 1012 (15) 2.3 [1.6–3.1] <0.001
Bilateralityc
Yes 51 11 (22) 2550 215 (8) 2.9 [1.5–5.6] 0.001d
No 149 45 (30) 7450 1136 (15) 2.3 [1.7–3.2] <0.001
aBased on 217 MTC patients with pertinent data and their corresponding reference population.
bBased on 219 MTC patients with pertinent data and their corresponding reference population. Staging was based on the American Joint
Committee on Cancer seventh and eighth editions (28,29).
cBased on 200 MTC patients, who underwent total thyroidectomy and their corresponding reference population.
dRobust standard errors were used in the Cox model to take into account the added uncertainty provided by deviations from the
proportional hazards assumption.
MTC, medullary thyroid carcinoma; HMTC, hereditary MTC; SMTC, sporadic MTC; HR, hazard ratio; CI, confidence interval.
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Discussion
This nationwide study reports for the first time at a popu-
lation level that absence of regional lymph node metastasis is
a significant predictor for long-term biochemical cure. The
results also indicate that patients diagnosed with HMTC by
screening, patients without regional metastases, and patients
with stages I, II, and III disease may have an overall survival
similar to that of the general population.
Limitations
For optimal assessment of overall survival between the
MTC subgroups and the reference population, it would have
been preferable for both populations to be have been fol-
lowed until all patients had died in one of the cohorts. Such
follow-up, potentially spanning half a century or more, was
impossible in this study, since the first patient included was
from 1997. However, complete follow-up of both cohorts has
been provided until January 1, 2018.
Due to the founder effect of the C611Y mutation in Den-
mark, a large proportion of the Danish multiple endocrine
neoplasia type 2A (MEN2A) cohort comprise patients with
RET mutations classified in the American Thyroid Associa-
tion moderate risk level (7,39,40). Other MEN2A cohorts
contain large proportions of carriers with mutations (codon
634) classified in the high risk level (27,41). Thus, assuming
that MEN2A cohorts in general mirror the HMTC cohorts,
the HMTC cohort in this study may not be representative of
other HMTC cohorts. Therefore, it could be argued that the
HMTC results predominantly apply for HMTC populations
carrying moderate risk mutations, a fact that should be
taken into consideration when interpreting the results. On the
other hand, the distribution of carriers with moderate risk
versus high risk mutations may be of lesser importance than
Table 3. Disease-Specific Survival and Prognostic Factors in Patients with Medullary
Thyroid Carcinoma in Denmark, 1997–2014
Disease-specific survival, % (n = 220) Univariate (n = 220) Multivariate (n = 217)
Factors 5-year 10-year 15-year 20-year HR [CI] p-Value HR [CI] p-Value
Sex
Female 87 83 83 79 1 1
Male 73 61 54 54 2.6 [1.5–4.5] 0.001 2.4 [1.3–4.4) 0.005
Age at diagnosis (years)
<21 93 93 93 1 1
21–40 93 87 87 87 1.6 [0.2–13.3] 0.686 0.6 [0.1–7.1] 0.711
41–60 85 80 71 64 3.5 [0.5–26.3] 0.224 1.1 [0.1–11.0] 0.963
>60 67 54 54 8.7 [1.2–64.5] 0.034 2.8 [0.3–29.4] 0.380
MTC type
HMTC, by screening 100 96 96 96 1 1
HMTC, by symptoms 77 77 77 8.8 [0.8–97.1] 0.076 5.3 [0.5–61.3] 0.182
SMTC 77 69 64 15.9 [2.2–115.5] 0.006 4.9 [0.6–42.9] 0.148
T categorya
T1 93 91 91 91 1 1
T2 86 78 68 58 3.3 [1.3–8.2] 0.009 2.1 [0.8–5.5] 0.129
T3 71 64 64 4.7 [1.7–12.9] 0.003 2.3 [0.8–6.7] 0.115
T4 57 43 43 10.4 [4.4–24.4] <0.001 2.9 [1.2–7.2] 0.022
N category
N0 95 93 91 87 1 1
N1 70 58 54 54 6.1 [2.9–13.0] <0.001 2.7 [1.1–6.4] 0.025
M category
M0 89 82 79 76 1 1
M1 14 20.4 [10.8–38.5] <0.001 12.3 [6.0–25.0] <0.001d
TNM stageb
I 98 98 98 98 1
II 97 93 87 78 5.4 [0.6–48.3] 0.132
III 94 87 87 87 6.9 [0.6–76.6] 0.114
IV 64 53 49 31.8 [4.4–231.4] 0.001
Multifocalityc
No 91 82 77 1
Yes 83 78 78 78 1.2 [0.6–2.4] 0.636
Bilateralityc
Yes 86 79 79 79 1
No 89 81 76 1.1 [0.5–2.3] 0.889
aBased on 217 patients with pertinent data.
bBased on 219 patients with pertinent data. Staging was based on the American Joint Committee on Cancer seventh and eighth editions
(29,30).
cBased on 200 patients, who underwent total thyroidectomy.
dSignificant after Bonferroni correction (31).
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previously thought due to recent evidence suggesting simi-
larly aggressive clinical courses among patients with muta-
tions from either risk level (42).
In the analysis of predictors for disease-specific survival, a
larger sample size or longer follow-up may have provided
more events and thus greater statistical strength. Conse-
quently, predictors dismissed as significant after Bonferroni
correction may have proven significant in an optimal setting.
It also cannot be ruled out that a small proportion in the
cohort with long-term biochemical cure may develop bio-
chemical recurrence eventually. However, with a biochemi-
cal follow-up of at least two years and no treatment other than
initial surgery in 99% (69/70) of the patients, this proportion
is likely very low.
Characteristics
The MTC cohort is comparable to other large population-
based MTC cohorts with regard to female-to-male ratio
(6,9,43,44), age at diagnosis (6,9,43,44), distribution of MTC
type (6,11,13), rates of disease-specific survival (11,12,45,46),
and rates of biochemical cure (12). Concerning TNM stage, the
cohort seems to differ from others (43), having a higher pro-
portion of stage IV patients, presumably due to a high pro-
portion of T4 and N1b (82% of all N1) patients. Also, the
composition of the HMTC cohort likely differs from others due
to the Danish RETC611Y founder effect causing an unusual high
incidence of C611Y carriers in Denmark (39,40).
Notably, the age of HMTC patients diagnosed by screening
did not differ compared to that of HMTC patients diagnosed by
symptoms. Furthermore, 40% of HMTC patients diagnosed by
screening had regional lymph node metastases. Altogether, this
suggests that the diagnosis of HMTC by screening was made
relatively late. In fact, this was the case, as the HMTC patients
diagnosed by screening primarily comprised siblings, cousins,
and parents to MEN2 index patients who were diagnosed with
the syndrome at a relatively late age. This relatively late age at
diagnosis of HMTC in patients detected by screening allows for
the development of advanced disease and is probably also the
reason for the rather low rate of long-term biochemical cure in
HMTC patients diagnosed by screening.
Survival
The Danish MTC cohort from 1997 to 2014 had a signifi-
cantly worse overall survival compared to that of the general
population. Not surprisingly, similar results have been demon-
strated for other MTC cohorts (2–6). In the meantime, survival
in HMTC patients diagnosed by screening was comparable to
that of the general population. To date, only one other study has
conducted a similar analysis (6). The results were equivalent to
those of the current study. This study, however, strengthens the
results of the other study further, as the HMTC diagnosis in the
present cohort was verified by RET germline mutations, while
the HMTC diagnosis in the other study was attached with
considerable uncertainty because it was based solely on histo-
pathological parameters, family history, and additional features
of MEN2. To the best of the authors’ knowledge, the present
study is the first to show explicitly that patients without regional
lymph node metastases have survival similar to that of the
general population. This could likely be explained by the high
rate of biochemical cure in this subgroup. It was also found that
patients with stages I, II, and III disease had similar survival as
the general population. This could indicate a negative impact on
overall survival of T4 tumors and N1b and M1 disease, as these
are absent in stages I, II, and III (47). Comparison to other
studies is complicated by the use of different staging systems,
thus hindering reasonable conclusions (2–4,6).
In univariate analysis, SMTC predicted poorer disease-
specific survival (hazard ratio = 6.5 [CI 2.0–21.0]) compared
to HMTC. The difference, however, disappeared in multi-
variate analysis. This is supported by a number of studies
also finding no difference in survival between SMTC and
HMTC patients after adjustment for age and stage at diagnosis
(12,13,48–50).
Table 4. Characteristics of 194 Patients Evaluated
for Long-Term Biochemical Cure
a
Following
Diagnosis of Medullary Thyroid Carcinoma
in Denmark, 1997–2014
Characteristics
Cured Not cured
(n = 70) (n = 124)
At diagnosis
Sex, n (%)
Female 49 (70) 69 (56)
Male 21 (30) 55 (44)
Age (years), median (IQR) 46 (35–57) 54 (40–66)
MEN2 syndrome, n (%)
MEN2A 17 (89) 27 (84)
MEN2B 2 (11) 5 (16)
MTC type, n (%)
HMTC, by screening 18 (26) 23 (19)
HMTC, by symptoms 1 (1) 9 (7)
SMTC 51 (73) 92 (74)
Thyroid surgery, n (%)
Total thyroidectomy 70 (100) 124 (100)
Lymph node surgery, n (%)
No lymph node surgery 15 (21) 12 (10)
Lymph node extirpation 17 (24) 14 (11)
Modified neck dissection 38 (54) 81 (65)
Classic neck dissection 0 17 (14)
T category, n (%)
T0 0 1 (1)
T1 45 (64) 40 (32)
T2 16 (23) 35 (28)
T3 7 (10) 17 (14)
T4 1 (1) 31 (25)
Tx 1 (1) 0
N category, n (%)
N0 65 (93) 29 (23)
N1 5 (7) 95 (77)
M category, n (%)
M0 70 (100) 116 (94)
M1 0 8 (6)
TNM stage,b n (%)
I 43 (61) 10 (8)
II 20 (29) 18 (15)
III 3 (4) 13 (10)
IV 3 (4) 83 (67)
Unknown 1 (1) 0
Due to rounding up, not all sums of percentages fit.
aLong-term biochemical cure was defined as undetectable basal
serum calcitonin at last biochemical follow-up in patients who had
received no other treatment besides initial surgery.
bStaging was based on the American Joint Committee on Cancer
seventh and eighth editions (29,30).
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On multivariate analysis, it was found that the presence
of distant metastases significantly predicts worse disease-
specific survival. This is in accordance with other recent
population-based studies (9,10). As in other studies (9,10),
the presence of regional metastatic disease in the Danish
cohort was a weaker prognostic indicator ( p = 0.025). An-
other weak predictor of adverse outcome was male sex
( p = 0.005). Contradictory results have been found in other
studies (8,10,12). To the best of the authors’ knowledge, only
one research group has previously reported male sex as a
significant predictor ( p = 0.0001) for disease-specific mor-
tality at a population level (11). Our result, however, could
not replicate this after Bonferroni correction. Accordingly,
the influence of sex still seems unclear.
By incorporating age as a continuous rather than categorical
variable in the multivariate analysis, younger age at diagnosis
significantly predicted better disease-specific survival, even
after Bonferroni correction. Younger age, however, may be
conceived as a surrogate of early diagnosis in HMTC patients
and perhaps also in SMTC patients. Recently, a large German
study of 600 SMTC patients demonstrated a significant increase
in the rate of MTC microcarcinomas and biochemical cure
paralleled by significant declines in the proportion of node-
positive patients and patients with distant metastases from 1995
to 2015 (51). These data support a time trend toward earlier
detection of SMTC in Germany. The authors suggested that the
trends possibly reflect greater use of calcitonin screening in
patients with nodular disease on top of ultrasonography of the
Table 5. Analysis of Prognostic Factors for Long-Term Biochemical Curea in Patients who had Undergone
Total Thyroidectomy for Medullary Thyroid Carcinoma in Denmark, 1997–2014
Univariate (n = 194) Multivariate (n = 192)
Factors OR [CI] p-Value OR [CI] p-Value
Sex
Female 1.9 [0.999–3.5] 0.051 1.1 [0.4–2.9] 0.867
Male 1 1
Age at diagnosis (years)
<21 1.7 [0.5–6.1] 0.381 5.8 [0.6–53.1] 0.120
21–40 2.9 [1.3–6.6] 0.013 2.5 [0.6–10.3] 0.197
41–60 1.9 [0.9–4.1] 0.087 1.1 [0.4–3.3] 0.844
>60 1 1
MTC type
HMTC, by screening 7.0 [0.8–60.8] 0.076 2.1 [0.1–38.0] 0.696
HMTC, by symptoms 1 1
SMTC 5.0 [0.6–40.5] 0.133 3.4 [0.1–86.6] 0.454
T categoryb
T1 34.9 [4.6–267.2] 0.001 11.3 [0.96–131.6] 0.054
T2 14.2 [1.8–113.1] 0.012 2.4 [0.2–27.0] 0.479
T3 12.8 [1.4–112.6] 0.022 4.0 [0.3–54.1] 0.291
T4 1 1
N category
N0 42.6 [15.7–115.8] <0.001 40.1 [12.0–133.7] <0.001e
N1 1 1
M categoryc
M0
M1
TNM staged
I 118.97 [31.1–455.1] <0.001
II 30.7 [8.2–114.6] <0.001
III 6.4 [1.2–35.1] 0.033
IV 1
Multifocality
No 3.7 [1.8–7.6] <0.001 5.0 [1.2–20.1] 0.024
Yes 1
Bilaterality
Yes 1
No 1.8 [0.9–3.7] 0.110
aLong-term biochemical cure was defined as undetectable basal serum calcitonin at last biochemical follow-up in patients who had
received no other treatment besides initial surgery.
bBased on 192 patients with pertinent data.
cAnalyses could not be performed as no patients with distant metastases were biochemically cured.
dBased on 193 patients with pertinent data. Staging was based on the American Joint Committee on Cancer 7th and 8th edition (29,30).
eSignificant after Bonferroni correction (31).
OR, odds ratio.
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neck. Conducting corresponding analyses on both the SMTC
and overall MTC cohort failed to identify similar significant
time trends (data not shown). This may in part be due to the
limited sample size, but another likely explanation is that cal-
citonin screening in patients with nodular thyroid disease in
Denmark is not routinely used. As such, implementation of
routine calcitonin screening in Denmark may potentially en-
hance biochemical cure rates in SMTC patients to the level
reported in the German study.
Biochemical cure
Prognostic factors for long-term biochemical cure were
analyzed for the first time in an unselected cohort at a popu-
lation level. On multivariate analysis after Bonferroni adjust-
ment, regional lymph node metastasis was found to be the only
significant predictor ( p < 0.001). Only one other population-
based study has investigated prognostic factors for biochemi-
cal cure (12). Their results showed that stage at surgery was the
only significant indicator for biochemical cure initially post-
operatively. However, the study was limited by an inclusion of
only 36% of all potential MTC patients and did not elaborate
on the stage subgroups. When considering institutional series
investigating the association between nodal metastasis and
biochemical cure by multivariate analysis, the present results
are in keeping with most (18,52–54), but not all studies (55).
Disagreement with the latter study may be explained by a
difference in study cohorts, as the latter study only included
patients with tumor size <1.6 cm. Of note, five patients in the
present cohort with node-positive MTC achieved long-term
biochemical cure. In these patients, the number of metastatic
lymph nodes did not exceed four. Conversely, no patients with
more than four positive lymph nodes were cured. Corre-
sponding trends have been demonstrated in institutional series
(52,53,56,57). Two of these found that initial postoperative
biochemical cure was virtually impossible in patients with >10
lymph node metastases but could be obtained in 31% (8/26)
and 57% (17/30) of patients with <10 lymph node metastases
(56,57). One study, also investigating initial postoperative
biochemical cure, found a mean of 1.5 and 12.0 positive lymph
nodes in cured and not cured patients, respectively (53). An-
other study, reporting on long-term biochemical cure, found a
mean of 2.4 and 10.1 metastatic lymph nodes in cured and not
cured patients, respectively (52). Combined with the results
from the present nationwide study, this lends hope that long-
term biochemical cure may be possible in MTC patients with
regional lymph node metastases. However, the number of
positive nodes has to be very low.
Conclusions
Patients with hereditary MTC diagnosed by screening,
patients without regional metastases, and patients with stages
I, II, and III disease may have similar survival as the general
population. The presence of distant metastases predicted
worse disease-specific survival, while the absence of regional
metastasis predicted long-term biochemical cure.
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